Memorial Sloan Kettering Cancer Center

Smit Shah

Research Technician



Currently, I am a Research Technician in Dr. Gabriela Chiosis' Research group at Memorial Sloan Kettering Cancer Center. Research in our laboratory is focused on the development of HSP70, HSP90 and GRP94 modulators as anticancer agents. To this end, I am adept at conducting numerous pre-clinical studies such as *in vitro* binding affinity, cytotoxicity, *in-vitro* permeability assay, PK/PD and toxicology analysis of the inhibitors, and have learned several techniques that will enable me to carry out my duties diligently. These techniques include cell and tissue culture, werstern blot, fluorescence polarization (FP), microsomal stability, CYP inhibition, HERG inhibition, PAMPA and other key assays intended to evaluate the potential of a molecule. Additionally, I have considerable experience in animal handling, development of tumor xenograft in animal and organ harvesting to determine biodistribution of drug. I also have hands on experience in operating various analytical instruments such as LC-MS/MS for PK analysis, Analyst multimode microplate reader with fluorescence polarization, absorbance, fluorescence, FRET and chemiluminescence capabilities.

Current Position
SAS Programmer at WCCT Global

Publications

Kishinevsky S, Wang T, Rodina A, Chung SY, Xu C, Philip J, Taldone T, Joshi S, Alpaugh ML, Bolaender A, Gutbier S, Sandhu D, Fattahi F, Zimmer B, Shah SK, Chang E, Inda C, Koren J, Saurat NG, Leist M, Gross SS, Seshan VE, Klein C, Tomishima MJ, Erdjument-Bromage H, Neubert TA, Henrickson RC, Chiosis G, Studer L. HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nature Communications. 2018;9(1):4345.

Patel HJ, Patel PD, Ochiana SO, Yan P, Sun W, Patel MR, Shah SK, Tramentozzi E, Brooks J, Bolaender A, Shrestha L, Stephani R, Finotti P, Leifer C, Li Z, Gewirth DT, Taldone T, Chiosis G. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. J Med Chem. 2015;58(9):3922-43. PubMed PMID: 25901531; PMCID: PMC4518544.

Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol Oncol. 2014;8(2):323-36. PubMed PMID: 24388362; PMCID: PMC3982393.

Taldone, Tony; Patel, Pallav; Patel, Maulik; Patel, Hardik; Evans, Christopher; Rodina, Anna; Stefan Ochiana, Smit K. Shah; Uddin Mohhamad, Gewirth, Daniel; Chiosis, Gabriela. Experimental and structural testing module to analyze paralog- specificity and affinity in the Hsp 90 inhibitors series. *J. Med. Chem.*, 2013, 56 (17), 6803-6818

Srikanth R. Ambati; Eloisi Caldas, Lopes; Kohji, Kosugi; Ullas, Mony; Ahmet, Zehir; Smit K. Shah; Tony, Taldone; Andre, Moreira; Paul A. Meyers; Gabriela, Chiosis; Malcolm A. Moore. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. *Mol. Oncol.,* 2013 Dec 15. pii: S1574-7891(13)00177-4. doi: 10.1016/j.molonc.2013.12.005..